Chemotherapy Regimens Received by Women With BRCA1/2 Pathogenic Variants for Early Stage Breast Cancer Treatment.

JNCI Cancer Spectr · 2022 · PMC9305849 · PMID 35723570

Europe PMC DOI

hedged sentence

0.2700

closest p · 5.4× alpha

0.2700

boldest claim

The sentences

did not reach statistical significanceP = .27not close (p > 0.1)

Among women with TNBC, receipt of a more intensive chemotherapy regimen varied somewhat by genetic result but did not reach statistical significance ( BRCA1/2 PV carriers OR = 1.66, 95% CI = 0.97 to 2.82; P = .27).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.